21,544 Shares in Vericel Co. (NASDAQ:VCEL) Purchased by Dynamic Technology Lab Private Ltd

Dynamic Technology Lab Private Ltd acquired a new position in shares of Vericel Co. (NASDAQ:VCEL - Free Report) in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund acquired 21,544 shares of the biotechnology company's stock, valued at approximately $910,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. International Assets Investment Management LLC grew its holdings in Vericel by 4,126.7% during the 3rd quarter. International Assets Investment Management LLC now owns 634 shares of the biotechnology company's stock valued at $27,000 after buying an additional 619 shares during the last quarter. CWM LLC grew its holdings in Vericel by 319.0% during the 2nd quarter. CWM LLC now owns 662 shares of the biotechnology company's stock valued at $30,000 after buying an additional 504 shares during the last quarter. Farther Finance Advisors LLC grew its holdings in Vericel by 48.1% during the 3rd quarter. Farther Finance Advisors LLC now owns 1,247 shares of the biotechnology company's stock valued at $53,000 after buying an additional 405 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Vericel by 22.2% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,773 shares of the biotechnology company's stock worth $77,000 after purchasing an additional 322 shares during the last quarter. Finally, Meeder Asset Management Inc. acquired a new stake in shares of Vericel during the third quarter worth $92,000.

Insider Buying and Selling at Vericel

In other news, Director Steven C. Gilman sold 5,833 shares of Vericel stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $40.35, for a total transaction of $235,361.55. Following the sale, the director now directly owns 11,000 shares of the company's stock, valued at approximately $443,850. The trade was a 34.65 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Dominick Colangelo sold 17,500 shares of Vericel stock in a transaction dated Wednesday, October 16th. The stock was sold at an average price of $41.38, for a total value of $724,150.00. Following the sale, the chief executive officer now directly owns 220,937 shares in the company, valued at approximately $9,142,373.06. The trade was a 7.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 31,666 shares of company stock valued at $1,350,764 over the last three months. 7.20% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the company. Canaccord Genuity Group restated a "buy" rating and set a $60.00 price objective on shares of Vericel in a report on Tuesday, November 19th. BTIG Research raised their price objective on Vericel from $56.00 to $66.00 and gave the stock a "buy" rating in a report on Tuesday. TD Cowen raised their price objective on Vericel from $55.00 to $60.00 and gave the stock a "buy" rating in a report on Tuesday, August 27th. HC Wainwright reaffirmed a "buy" rating and issued a $60.00 target price on shares of Vericel in a research report on Friday, November 8th. Finally, Canaccord Genuity Group began coverage on Vericel in a research report on Friday, August 9th. They issued a "buy" rating and a $57.00 target price on the stock. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to MarketBeat.com, Vericel presently has a consensus rating of "Moderate Buy" and an average price target of $59.71.

Vericel Trading Down 1.7 %

NASDAQ:VCEL traded down $0.99 during mid-day trading on Thursday, hitting $57.76. The company had a trading volume of 328,045 shares, compared to its average volume of 431,669. The business has a fifty day simple moving average of $46.92 and a 200-day simple moving average of $47.22. Vericel Co. has a 1 year low of $32.31 and a 1 year high of $61.49. The firm has a market capitalization of $2.85 billion, a price-to-earnings ratio of 962.83 and a beta of 1.66.

Vericel (NASDAQ:VCEL - Get Free Report) last released its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.05) by $0.03. Vericel had a return on equity of 1.48% and a net margin of 1.56%. The company had revenue of $57.91 million for the quarter, compared to analyst estimates of $55.32 million. As a group, research analysts anticipate that Vericel Co. will post 0.13 earnings per share for the current year.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.